Background. Exogenous insulin-like growth factor-I (IGF-I) promotes recovery from ischemic renal injury, but its effect on cisplatin (CDDP)-induced nephrotoxicity and its mechanisms for the attenuation of renal injury are unknown. Methods. We administered recombinant human IGF-I (rhIGF-I, 150 µg/day, i.p.) once a day 24 h prior to and after CDDP (5 mg/kg, i.v.) injection in rats. Results. The rhIGF-I treatment significantly decreased serum creatinine (0.92 Ϯ 0.11 vs 1.50 Ϯ 0.15 mg/dl; P Ͻ 0.05), the tubular damage score, and the ratio of apoptotic cells to tubular epithelial cells in the outer stripe of the outer medulla on day 5 (P Ͻ 0.05). rhIGF-I significantly increased the numbers of p21-positive nuclei (5.15 Ϯ 0.19 vs 3.45 Ϯ 0.42/ϫ400 high-power field (HPF); P Ͻ 0.05) and proliferating cell nuclear antigen (PCNA)-positive nuclei (28.61 Ϯ 1.89 vs 18.26 Ϯ 2.14/ϫ400 HPF; P Ͻ 0.05), but decreased the number of cyclin D1-positive cells (3.3 Ϯ 0.3 vs 6.3 Ϯ 1.7/ ϫ400 HPF; P Ͻ 0.05) on day 3. rhIGF-I did not alter 5-bromo-3-deoxyuridine (BrdU) incorporation. Conclusions. Our findings suggested that rhIGF-I increased renal p21 and PCNA expression, but reduced cyclin D1 expression in CDDP-treated kidneys. Exogenous rhIGF-I may ameliorate renal damage, in part by stopping the cell cycle at G1/S phase.
Introduction
Acute renal failure (ARF) remains a potentially lifethreatening complication that occurs in about 5% of hospitalized patients and 30% of patients in intensive care units. 1 Cisplatin (cis-diamminedichloroplatinum (II) [CDDP] ) is widely used as a cytotoxic anticancer agent for the treatment of solid tumors, but its potent nephrotoxicity limits its use in therapeutically effective doses. Therefore, strategies designed to allow dose escalation may result in improved efficacy for malignant tumors. However, currently, there are no agents that attenuate the tubular damage caused by CDDP in the clinical setting.
Recently, abnormalities of the cell-cycle system were suggested to play a pathophysiological role in the development of acute renal injury. [2] [3] [4] The cyclin-dependent kinase (CDK) inhibitor, p21, is induced via p53 after DNA damage, and plays a key role in stopping the cell cycle at the G1/ S phase checkpoint by forming a ternary complex with various cyclin-CDK complexes, including cyclin D/CDK4, 6 and cyclin E/CDK2, thus inhibiting their enzymatic activity. We recently demonstrated that the upregulation of p21 attenuated CDDP-induced renal dysfunction, apoptosis, and tubular damage, indicating that p21 may protect against CDDP-induced renal injury. 5 Megyesi et al. 2, 6 also reported the cytoprotective role of p21 against ischemia/reperfusion injury and CDDP-induced nephrotoxicity, using p21 knockout mice.
Exogenous insulin-like growth factor-I (IGF-I), a 70-amino-acid single-chain polypeptide, is known to accelerate recovery from ischemic and mercury chloride-induced ARF. [7] [8] [9] [10] [11] Recombinant human IGF-I (rhIGF-I) has been shown to reduce apoptotic cell death following anoxiareoxygenation injury in rat primary cultured proximal tubular cells. 10 Therefore, IGF-I may have mitogenic and antiapoptotic actions on injured tubular cells.
The aim of the present study was to clarify IGF-I actions on cell-cycle regulation and DNA repair in the kidneys of CDDP-treated rats. We first evaluated the effects of exogenous rhIGF-I on CDDP-induced renal injury. We next examined changes in the renal expression of the cell-cycle regulators, p21 and cyclin D1, and a DNA repair marker, proliferating cell nuclear antigen (PCNA), following rhIGF-I administration in CDDP-treated kidneys.
Materials and methods

Induction of CDDP-ARF
A total of 63 male Sprague-Dawley rats, weighing 220 to 300 g (SLC, Hamamatsu, Japan), were provided with standard rat chow and drinking water ad libitum. ARF was induced by a single intravenous injection of CDDP [kindly provided by Nippon Kayaku, Tokyo, Japan] dissolved in sterile 0.9% saline (5 mg/kg body weight), given via the dorsal penile vein. We have previously reported that this CDDP dose resulted in a rise in serum creatinine and an increased tubular damage score and that these effects reached peak levels at day 5 postinjection but gradually returned to basal levels by day 14.
5,12, 13 We administered rhIGF-I [a kind gift from Fujisawa Pharmaceutical, Osaka, Japan] at 150 µg intraperitoneally, dissolved in 0.2 ml of sterile saline, or 0.2 ml sterile saline once a day 24 h prior to and after CDDP injection. The selected dose of rhIGF-I was previously reported to be effective against ischemic ARF in rats. 11 The rats were divided into three groups as follows: CDDP-alone group, CDDP-treated rats (n ϭ 25); CDDP-plus-rhIGF-I group, rhIGF-I plus CDDP-treated rats (n ϭ 23); and an rhIGF-I-alone group, rhIGF-I-treated control rats (n ϭ 15). Rats in each group were killed 1, 3, and 5 days after CDDP injection. One hour before being killed, they were intraperitoneally injected with 40 mg/kg of 5-bromo-3-deoxyuridine (BrdU; Sigma Chemicals, St. Louis, MO, USA) to allow for the examination of cells that had progressed into the S phase of the cell cycle. Blood samples were collected from the abdominal aorta for measuring the concentrations of serum creatinine and blood urea nitrogen (BUN) by automatic enzyme analyzer. Both kidneys were removed for morphological and immunohistochemical analyses. The experimental protocol was approved by the Ethics Review Committee for Animal Experimentation of Hamamatsu University School of Medicine.
Histological examination
Kidney tissues were fixed in 4% paraformaldehyde and embedded in paraffin. For histological examination, 3-µ-m thick sections of renal tissue were counterstained with periodic acid-Schiff reagent. Because CDDP induces tubular damage most prominently in the outer stripe of the outer medulla, 5, 6, 12, 13 we conducted a semiquantitative histological analysis in this area. One hundred tubules in each kidney were randomly selected at ϫ400 magnification in this field, and the degree of tubular damage was scored. Each tubular profile was assigned one of five categories using the following criteria: 0, normal; 1, areas of tubular epithelial cell swelling, vacuolar degeneration, necrosis, and desquamation involving less than 25% of the tubular profile; 2, similar changes involving 25% or more but less than 50% of the tubular profile; 3, similar changes involving 50% or more but less than 75% of the tubular profile; and 4, similar changes involving 75% or more of the tubular profile, as described previously. 5, 13 To minimize observer bias, the morphometric examination was performed in a blinded fashion by a person without any knowledge of the treated group from which the tissue originated. We calculated the mean tubular damage score in each rat, and then determined the mean score for each group.
Immunohistological studies
For the immunohistological detection of p53, p21, cyclin D1, BrdU, and PCNA, the paraffin samples were cut at 3 µm, deparaffinized, and rehydrated. After endogenous peroxidase was quenched with 3% hydrogen peroxide, the slides were preincubated with 10% normal donkey serum to block nonspecific reaction. The samples were then incubated with a polyclonal antibody against p53 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 1 h at 37∞C, a polyclonal antibody against cyclin D1 (Santa Cruz Biotechnology) overnight at 4∞C, a monoclonal antibody (mAb) against p21 (Santa Cruz Biotechnology) overnight at 4∞C, a mAb against PCNA (Oncogene Science, Uniondale, NY, USA) for 30 min at 37∞C, or a mAb against BrdU (Amersham International, Buckinghamshire, UK) for 1 h at 37∞C. After a washing in phosphate-buffered saline (PBS; pH 7.4), the samples were incubated with biotinconjugated donkey anti-mouse IgG or anti-rabbit IgG (Chemicon International, Temecula, CA, USA) for 30 min at room temperature, washed in PBS, and then incubated with streptavidin-conjugated peroxidase for 30 min. Finally, the reaction products were visualized using hydrogen peroxide containing 3,3Ј-diaminobenzidine in 0.05 M Tris buffer. Control sections were incubated overnight using phosphate buffer solution instead of the primary antibody.
Assessment of apoptosis
The extent of apoptosis was assessed using a terminal uridine nick-end labeling (TUNEL) technique. The tissue was deparaffinized and rehydrated, followed by the incubation of 3-µm-thick sections with 20 µg/ml proteinase K for 15 min and immersion in distilled water containing 3% hydrogen peroxide for 10 min at room temperature. Detection of DNA fragmentation was performed using ApopTag plus an in situ Apoptosis Detection Kit (Intergen, Purchase, NY, USA). We also directly counted the number of apoptotic cells under light microscopy by high magnification, because TUNEL staining can occasionally be nonspecific. The definition of apoptosis in cells was based on the presence of at least one of the following morphological criteria: (1) cellular rounding and shrinkage; (2) eosinophilic cytoplasm; (3) nuclear chromatin compaction, especially along the nuclear envelope, in a crescent manner; membrane-bound cellular blebbing; and (4) formation of classic apoptotic bodies, as described in previous studies. 14 We only evaluated tubular cells that were located in the tubular epithelium, and not those that had become detached and/or had dropped off into the tubular lumen.
A semiquantitative analysis was performed by counting TUNEL-positive cells, morphologically defined apoptotic tubular epithelial cells, and tubular epithelial cells per one field at ϫ400 magnification in the outer stripe of the outer medulla. We counted 20 randomly selected fields in each kidney, and expressed the results as the mean ratio of TUNEL-positive or morphologically apoptotic cells relative to the total number of tubular epithelial cells.
Isolation and quantitative analysis of p21 mRNA by real-time reverse transcription-polymerase chain reaction (RT-PCR) Total RNAs were extracted from whole kidneys in each rat (n ϭ 3), using ISOGEN (Nippon Gene, Tokyo, Japan) according to the protocol provided by the manufacturer. Poly-Aϩ -enriched RNA was obtained by binding to oligo (dT) cellulose beads. The mRNA samples were quantified by spectrophotometry at 260 nm. The mRNA samples were reversibly transcribed into cDNA using a First Strand cDNA Synthesis Kit for RT-PCR (Roche, Mannheim, Germany). Real-time PCR was performed in a Light Cycler (Roche). All PCR experiments were performed using the QuantiTect SYBR Green PCR kit, purchased from QIAGEN (Tokyo, Japan). The amplification program consisted of 1 cycle at 95∞C with a 7-min hold (hot start), followed by 50 cycles at 95∞C with a 15-s hold, 58∞C annealing temperature with a 5-s hold, and 72∞C with a 20-s hold. Amplification was followed by a melting curve analysis to verify the accuracy of the amplicon. The primers for p21 were 5Ј-TAAGGCAGAA GATGGGGAAGAG-3Ј(sense) and 5Ј-ACGTGGCCTT GTCGCTGTCTT-3Ј(antisense). A negative control with mRNA was run to assess its specificity for reaction. For verification of the correct amplification, PCR products were analyzed on an ethidium bromide-stained agarose gel.
Data analysis was performed using Light Cycler software, version 3.3.9, provided by Roche. After a melting curve analysis was carried out, standard curves for p21 and glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) were generated by using PCR products of whole kidney mRNA as a template. The ratio of p21 mRNA to GAPDH mRNA was then calculated in each sample.
Statistical analysis
All data values were expressed as means Ϯ SEMs. Significant differences among data were determined using oneway analysis of variance (ANOVA) with standard post-hoc testing (Statview, version 5.0; Abacus Concepts, Berkeley, CA, USA). A P value of less than 0.05 denoted the presence of a statistically significant difference.
Results
Effect of rhIGF-1 on CDDP-induced renal injury
All animals were alive until 5 days after CDDP injection. There was no significant difference in body weight on day 5 after CDDP injection between the CDDP-alone group and the CDDP-plus rhIGF-I group (236 Ϯ 5.6 vs 242 Ϯ 4.0 g). The percentage reduction of body weight over 5 days was identical in both CDDP-treated groups (data not shown). Intermittent injection of rhIGF-I did not induce hypoglycemia in this study (data not shown).
Serum creatinine and blood urea nitrogen (BUN) progressively and significantly increased until day 5 after CDDP injection, as described previously. 6, 14, 15 On day 3, equivalent increases in serum creatinine (0.471 Ϯ 0.053 vs 0.532 Ϯ 0.047 mg/dl) and BUN (34.15 Ϯ 3.14 vs 33.98 Ϯ 3.27 mg/dl) occurred in the CDDP (n ϭ 10) and CDDPplus-rhIGF-I groups (n ϭ 10; Fig. 1 ). On day 5, however, significantly lower serum creatinine (0.923 Ϯ 0.113 vs 1.50 Ϯ 0.150 mg/dl; P Ͻ 0.05) and BUN (53.40 Ϯ 3.58 vs 76.77 Ϯ 3.75 mg/dl) levels were found in the CDDP-plus-rhIGF-I group (n ϭ 10) compared to the CDDP-alone group (n ϭ 10; Fig. 1 ). Injection of rhIGF-I did not change blood creatinine and BUN levels in CDDP-untreated rats (n ϭ 5; Fig. 1 ).
Histological examination revealed marked tubular damage in the outer stripe of the outer medulla in the CDDPalone group (Fig. 2A) . On day 3, there was no difference in the tubular damage score between the two CDDP-treated groups, but a significant reduction was found on day 5 in the CDDP-plus-rhIGF-1 group compared with the CDDPalone group (Table 1, Fig. 2B ). CDDP gradually increased the percentage of apoptotic cells relative to the total number of tubular epithelial cells until day 5 (Table 1, Fig. 2D ). Treatment with rhIGF-I significantly attenuated the CDDPinduced increase in TUNEL-positive cells located among tubular epithelial cells in the outer stripe of the outer medulla on day 5 (P Ͻ 0.05; Table 1 ). The number of apoptotic cells detected by light microscopy in the tubular epithelium was also significantly lower in the CDDP-plus-rhIGF-I group on day 5 (P Ͻ 0.05; Table 1 ). The injection of rhIGF-I in normal rats did not cause any tubular damage or apoptotic cell death during the observation period (Table 1 ).
Changes in cell-cycle markers in CDDP nephrotoxicity
Administration of CDDP rapidly and significantly increased the number of p53-positive nuclei in the outer stripe of the outer medulla, relative to the number at baseline, on day 1 (57.0 Ϯ 9.2 vs 0.0 Ϯ 0.0/ϫ400 HPF; P Ͻ 0.01; n ϭ 5; Figs. 3A and 4A ). The number of p53-postive cells markedly decreased by day 3 (8.4 Ϯ 0.5/ϫ400 HPF; n ϭ 10), and was further diminished on day 5 (3.9 Ϯ 0.9/ϫ400 HPF; n ϭ 10), compared to day 1, but no differences were found during the 5-day study period between the CDDP-alone and CDDP-plus-rhIGF-I-treated groups in the number of p53-positive nuclei (Fig. 4A) .
The number of p21-positive tubular cells was significantly higher on day 1, and further increased by day 3 (Figs. 3C and 4B), compared with the baseline number. This number of p21-positive cells in the outer medulla was comparable to the findings in previous studies.
2,5,6 Administration of rhIGF-I significantly increased the number of p21-positive cells on day 3 following CDDP administration (5.1 Ϯ 0.2 vs 3.5 Ϯ 0.4/ϫ400 HPF; n ϭ 10; P Ͻ 0.05). On day 5, the number of p21-positive cells was also higher in the CDDPplus-rhIGF-I group compared with the CDDP-alone group (4.2 Ϯ 0.5 vs 3.2 Ϯ 0.7/ϫ400 HPF; n ϭ 10), but the difference was not significant (Fig. 4B) .
A significant increase in p21 mRNA was found in both ARF groups compared to the rhIGF-1-alone group on days 1 and 3 (n ϭ 5). However, there was no significant difference in p21 mRNA between the CDDP-alone group and the CDDP-plus-rhIGF-1 group (n ϭ 5; Fig. 5 ).
Cyclin D1-positive tubular cells were observed on days 1, 3 and 5 following CDDP administration in the CDDP-alone group (Figs. 3E and 4C) . In contrast to the p21 findings, rhIGF-I treatment significantly decreased the number of cyclin D1-positive tubular cells on day 3 (3.3 Ϯ 0.3 vs 6.3 Ϯ 1.7/ϫ400 HPF; n ϭ 10; P Ͻ 0.05; Fig. 4C) .
In normal rats, daily injection of rhIGF-I did not increase the numbers of p53-, p21-, and cyclin D1-positive cells, and very few positive nuclei were observed in the kidney (n ϭ 5; Fig. 4 ).
Changes in PCNA and BrdU expression by rhIGF-I treatment CDDP progressively and significantly increased the number of PCNA-positive tubular cells in the kidney until day 5 (Fig. 6A,B) . Quantitative analysis showed a significant increase of PCNA-positive nuclei on day 3 in the CDDP-plusrhIGF-I group compared to the CDDP-alone group (28.6 Ϯ 1.9 vs 18.3 Ϯ 2.1/ϫ400 HPF; P Ͻ 0.05; n ϭ 10; Fig. 7A ). On day 5, however, the number of PCNA-positive cells was identical in the two CDDP-treated groups (n ϭ 10). Administration of rhIGF-I to normal rats did not increase the In contrast to the findings for PCNA, the number of BrdU-incorporated nuclei on day 3 was lower in the CDDPplus-rhIGF-I group than in the CDDP-alone group, though the difference was not significant (Fig. 6C, D, Fig. 7B ). In control rats, BrdU incorporation into tubular cells was noted in only a few nuclei in the kidneys of rats treated with rhIGF-I (Fig. 7B) .
Discussion
In the present study, we showed that exogenous rhIGF-I treatment attenuated the development of CDDP-induced renal injury. Intermittent rhIGF-I treatment significantly ameliorated CDDP-induced functional and morphological damage on day 5. In addition, we found that rhIGF-I treatment significantly increased the number of tubular cells A, B, C, D, E, F ϫ400 positive for p21 and PCNA in the outer stripe of the outer medulla on day 3, while significantly reducing the number of cyclin D1-positive cells. Administration of rhIGF-I did not change the CDDP-induced overexpression of p53 and BrdU incorporation until day 5. Considered together, our findings suggest that: (1) the beneficial effect of rhIGF-I against CDDP nephrotoxicity was associated with enhanced p21 and suppressed cyclin D1 expression in the early phase, (2) the rhIGF-I-induced upregulation of p21 A, B, C, D, ϫ200 ; E, F ϫ400 was independent of p53 expression, (3) rhIGF-I increased the number of PCNA-positive cells without any increase in BrdU incorporation, and (4) rhIGF-I may ameliorate CDDP-induced nephrotoxicity by cell-cycle arrest at the G1 phase, thereby enhancing DNA repair via PCNA in damaged tubular cells.
Previous studies have reported the effectiveness of exogenous rhIGF-I for renal function and histology in toxic, 9 ischemic, 7, 8, 10, 11 and ureteral obstruction injuries. 15 Mecha-nisms such as well-preserved renal hemodynamics 12, 16 and enhanced tubular cell mitogenicity 17 are suggested as explanations for the rhIGF-I-induced attenuation of acute renal injury. Additionally, rhIGF-I may increase the expression of renal osteopontin, which contains an Arg-Gly-Asp (RGD) cell adhesion motif and is implicated in tissue remodeling and repair in ischemic ARF. 18 rhIGF-I was also reported to lessen the inflammatory response in ischemic renal injury. 19, 20 p21 is a member of the CDK inhibitor protein family that also contains p27KIP1 and p57KIP2. p21 may be responsible for controlling the G1/S phase checkpoint in the event of DNA damage. In the present study, we found that rhIGF-I did not alter p53 expression in CDDP-treated rats, while it significantly increased the CDK inhibitor, p21, indicating that rhIGF-I increased renal p21 expression independent of p53. In addition, rhIGF-I significantly reduced the CDDP-induced increase of cyclin D1 expression in the early phase of ARF. These findings convincingly suggest that exogenous rhIGF-I enhanced p21 expression, but suppressed cyclin D1 expression in damaged tubular epithelial cells. These changes may lead to the arrest of CDDPexposed tubular epithelial cells in the G1 phase. Recent studies have demonstrated that different domains of p21 interact with CDKs and PCNA independently, and that both domains can inhibit DNA replication when present in cells. 21 The ability of p21 to bind simultaneously to both CDKs and PCNA suggests that it may mediate the coordination between DNA replication and repair and cell-cycle progression. 22 A similar nuclear distribution of p21 and PCNA is known to be dependent on the DNA-repair capacity of the cell after DNA damage. 23 IGF-I is reported to upregulate p21 protein expression in a muscle cell line. 24 However, it is not known whether rhIGF-I modulates the cell-cycle system in injured tubular epithelial cells. In the present study, we found that rhIGF-I increased the expression of both p21 and PCNA in the early phase of CDDP, without changing BrdU incorporation. These data suggest that the expression of both p21 and PCNA in damaged tubular cells may be associated with the facilitation of DNA repair. In this study, rhIGF-I did not increase the propor- A significantly higher number of p21-positive cells in the outer stripe of the outer medulla was found in the CDDPplus-rhIGF-1 group compared with the CDDP-alone group on day 3 (B). In contrast, rhIGF-I significantly reduced the number of cyclin D1-positive cells on day 3 (C). In normal rats, daily injection of rhIGF-I did not increase the number of p53-, p21-, or cyclin D1-positive cells in the kidney (A-C). Data values are means Ϯ SEM. * P Ͻ 0.05, CDDP-plusrhIGF-I group compared with CDDP-alone group on the same day. Symbols, as in Fig. 1 ; HPF, high-power field A significant increase in the number of PCNA-positive nuclei was detected in the CDDP-plus-rhIGF-I group on day 3 (A). In contrast, the number of BrdU-incorporated cells on day 3 was lower in the rhIGF-I-plus-CDDP group compared to the CDDP-alone group, though the difference was not significant (B). Data values are means Ϯ SEM. * P Ͻ 0.05, compared with CDDP-alone group. Symbols, as in Fig. 1 tions of p21-and PCNA-positive cells in normal tubular cells, possibly indicating that rhIGF-I may mainly work in acutely damaged tubular cells. Because exogenous rhIGF-I affects circulating IGF-binding proteins (IGFPs) and the gene expression of IGFPs in ischemic ARF kidneys, 25 it is possible that alterations in these regulatory factors may increase IGF-I action in damaged nuclei.
It is well known that both apoptosis and necrosis are observed as the forms of cell death associated with ARF. Recently, apoptosis was suggested to play a critical role in the development of ischemic and toxic ARF. 13, 19, 26 IGF-I is known to exert its antiapoptotic action via several mediators, such as Bcl-2, caspase 3, and Akt. 23, 27 Gobe et al. 14 demonstrated that the expression of IGF-I increased con-comitantly with anti-apoptotic Bcl-2 in adjacent proximal tubules 24 h after ischemia-reperfusion injury, a finding suggestive of paracrine actions in these tubules. In the present study, we showed that rhIGF-I reduced apoptotic cell death in association with cell-cycle coordination. Our study confirmed that CDDP injection increased renal p21 mRNA on days 1 and 3, as described previously. 3, 5 However, rhIGF-I did not alter the amount of p21 mRNA despite the increase in the number of p21-positive cells on day 3. The reasons for the lack of association between p21 mRNA and p21-positive nuclei are not clear at present. However, several studies have already reported this discrepancy, between the induced levels of p21 protein and its mRNA. 6, 28, 29 We also recently found that increased levels of p21 protein after repeated CDDP administration were not associated with increase in mRNA levels in the kidney. 5 Gorospe et al. 26 reported that p21 expression in DNA injury was regulated through a post-transcriptional mechanism, including stabilization of p21 mRNA. Therefore, IGF-I may work by stabilizing p21 protein through post-transcriptional regulation. However, we cannot exclude another possibility, that the method used in our study to evaluate the amount of p21 mRNA and protein was not appropriate to detect a small change of p21 mRNA.
In summary, our study is the first to demonstrate that the administration of exogenous rhIGF-I ameliorates CDDP-induced renal injury in rats. Daily treatment with rhIGF-I increased renal p21 and PCNA expression, but reduced cyclin D1 expression in CDDP-treated kidneys. These findings suggest that changes in these specific cell-cycle proteins in damaged tubular cells may be associated with the rhIGF-I-induced attenuation of CDDP nephrotoxicity.
